Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β<sup>0</sup>39-Globin Gene Editing and Induction of Fetal Hemoglobin.

Genes (Basel) · 2022 · PMC9601852 · PMID 36292612

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

highly significantp < 0.01actually significant

Statistical differences were considered significant when p < 0.05, highly significant when p < 0.01 [ 58 ]. 3.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.